Dupont Capital Management Corp Rigel Pharmaceuticals Inc Transaction History

Dupont Capital Management Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 26, 2022	SELL	$0.67 - $3.19 $40,987 - $195,148	-61,175 Closed	0 $0
Q1 2022 Apr 27, 2022	SELL	$2.22 - $3.45 $12,012 - $18,667	-5,411 Reduced 8.13%	61,175 $183,000
Q4 2021 Jan 31, 2022	SELL	$2.36 - $3.57 $237,512 - $359,288	-100,641 Reduced 60.18%	66,586 $176,000
Q3 2021 Nov 03, 2021	BUY	$3.5 - $4.5 $113,760 - $146,263	32,503 Added 24.13%	167,227 $607,000
Q1 2021 Apr 29, 2021	SELL	$3.35 - $4.93 $92,557 - $136,210	-27,629 Reduced 17.02%	134,724 $461,000
Q4 2020 Jan 28, 2021	SELL	$2.35 - $3.74 $28,474 - $45,317	-12,117 Reduced 6.95%	162,353 $568,000
Q3 2020 Oct 29, 2020	BUY	$1.78 - $4.13 $92,948 - $215,660	52,218 Added 42.71%	174,470 $419,000
Q2 2020 Jul 24, 2020	BUY	$1.41 - $2.05 $172,375 - $250,616	122,252 New	122,252 $224,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.84B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.